11 completed, 4 active not recruiting, 4 recruiting, 2 not yet recruiting. 10 Phase 3, 8 Phase 2, 6 Phase 1, 1 Phase 4.
Follow IBI362: new trials by email Literature Review of IBI362 trials Research Report on IBI362
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer Mazdutide(Dual GLP-1R/GCGR Agonist), Placebo, Levonorgestrel-releasing intrauterine system - Obesity, Overweight | Phase 2 | Not yet recruiting | Tongji Hospital | 128 | 2026-11-01 | 2026-08-24 |
| Mazdutide for Weight Management and Gout in Adults With Obesity Mazdutide - Gout, Obesity (BMI>30) | Phase 4 | Not yet recruiting | Hongwei Jiang | 30 | 2026-09-15 | 2026-09-17 |
| Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity IBI362, Placebo - Overweight, Obesity | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 336 | 2026-04-23 | 2026-05-27 |
| A Study of IBI362 in Chinese Adolescents With Obesity or Overweight Placebo, IBI362 - Adolescents With Obesity or Overweight With Weight-Related Comorbidities | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 180 | 2025-12-29 | 2026-01-08 |
| Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study) Mazdutide, Placebo - Dementia, Mild, Mild Cognitive Impairment | Phase 3 | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 420 | 2025-09-27 | 2026-09-02 |
| A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Placebo, IBI362 - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 181 | 2025-06-20 | 2026-10-20 |
| Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity Tirzepatide, Placebo, IBI362 - Obesity | Phase 1 / Phase 2 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 98 | 2025-06-17 | 2025-12-15 |
| A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 placebo, IBI362 - Sleep Apnea, Obstructive | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 260 | 2025-06-12 | 2025-06-29 |
| A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） IBI362, semaglutide - Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | Phase 3 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 479 | 2025-05-09 | 2026-05-12 |
| A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity placebo, IBI362 - Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF) | Phase 2 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 141 | 2025-03-26 | 2026-09-22 |
| This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity IBI362, IBI362 placebo - Adolescents With Obesity | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 36 | 2024-08-30 | 2025-09-12 |
| A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity IBI362, Semaglutide - Type 2 Diabetes, Obesity | Phase 3 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 349 | 2024-02-29 | 2026-06-11 |
| A Study of IBI362 9 mg in Chinese Adults With Obesity IBI362, Placebo - Obesity | Phase 3 | Unknown | Innovent Biologics (Suzhou) Co. Ltd. | 462 | 2023-12-27 | 2024-08-27 |
| Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment IBI362 - Renal Impairment | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 20 | 2023-05-05 | 2024-02-20 |
| A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects metformin, digoxin, IBI362 - Overweight Subjects, Obese Subjects | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 48 | 2023-04-06 | 2023-11-14 |
| A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise placebo, IBI362 - Type 2 Diabetes | Phase 3 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 319 | 2023-01-06 | 2024-08-20 |
| A Study of IBI362 in Participants With Type 2 Diabetes dulaglutide, IBI362 - Type 2 Diabetes | Phase 3 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 731 | 2023-01-06 | 2024-08-23 |
| A Study of IBI362 in Participants With Obesity or Overweight Placebo, IBI362 - Obesity Or Overweight | Phase 3 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 610 | 2022-11-14 | 2024-11-12 |
| A Study of IBI362 in Chinese Patients With Type 2 Diabetes IBI362, placebo, Dulaglutide - Type 2 Diabetes | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 252 | 2021-09-06 | 2023-12-27 |
| A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects IBI362, placebo - Overweight/ Obesity | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 328 | 2021-06-08 | 2025-11-17 |
Showing 20 of 22. Sign in to see all of them.
Obesity (9) · Diabetes Mellitus, Type 2 (6) · Overweight (4) · Cognitive Dysfunction (1) · Dementia (1) · Endometrial Hyperplasia (1) · Endometrial Neoplasms (1) · Gout (1) · Hyperuricemia (1) · Lymphoma, Follicular (1) · Metabolic Syndrome (1) · Renal Insufficiency (1) · Sleep Apnea Syndromes (1) · Weight Loss (1)
Innovent Biologics (Suzhou) Co. Ltd. (19) · Hongwei Jiang (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · Tongji Hospital (1)
China (21)
Gang Chen, Principal Investigator (1) · Hongwei Jiang, MD (1) · Lixin Guo, M.D (1) · Yan Bi, MD, PhD (1)
PMID 34430840, PMID 35750681, PMID 36247927, PMID 37943529, PMID 38092790, PMID 40421736, PMID 41407860, PMID 41875890, PMID 42251595